Par-Endo $8bn merger makes Mylan look undervalued
This article was originally published in Scrip
Executive Summary
In a deal that proves just what can be done when all shareholders can be consulted in a single elevator journey, Endo International and privately owned Par Pharmaceutical have put together a $8.05bn merger to create the fifth largest independent company in the generics pharmaceutical space. And the deal makes Teva's bid for Mylan look somewhat underpowered.